Increased activity of colistin in combination with amikacin against Escherichia coli co-producing NDM-5 and MCR-1

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 6, 2017, Pages 1723-1730

  Zhou, Yu Feng ^a   Tao, Meng Ting ^a   Feng, Youjun ^a,b   Yang, Run Shi ^a   Liao, Xiao Ping ^a   Liu, Ya Hong ^a   Sun, Jian ^a  

^a SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; COLISTIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA LACTAMASE NDM-5, E COLI; ESCHERICHIA COLI PROTEIN; MCR-1 PROTEIN, E COLI;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MONOTHERAPY; MOUSE; NONHUMAN; SIGMOID; UNBOUND FRACTION; ANIMAL; BIOSYNTHESIS; COMBINATION DRUG THERAPY; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

AMIKACIN; ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; MICE; MICROBIAL SENSITIVITY TESTS;

EID: 85027379393     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx038     Document Type: Article

References (39)

1. Van Duin D, Doi Y. Outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae: are we at the end of the road? J Clin Microbiol 2015; 53: 3116-7
2. Weiner LM, Webb AK, Limbago B et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol 2016; 37: 1288-301
3. Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601
4. Liu YY, Wang Y, Walsh TR et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016; 16: 161-8
5. Schwarz S, Johnson AP. Transferable resistance to colistin: a new but old threat. J Antimicrob Chemother 2016; 71: 2066-70
6. Ye H, Li Y, Li Z et al. Diversified mcr-1-harbouring plasmid reservoirs confer resistance to colistin in human gut microbiota. mBio 2016; 7: e00177
7. Yang RS, Feng Y, Lv XY et al. Emergence of NDM-5-and MCR-1-producing Escherichia coli clones ST648 and ST156 from a single Muscovy duck (Cairina moschata). Antimicrob Agents Chemother 2016; 60: 6899-902
8. Yao X, Doi Y, Zeng L et al. Carbapenem-resistant and colistin-resistant Escherichia coli co-producing NDM-9 and MCR-1. Lancet Infect Dis 2016; 16: 288-9
9. Du H, Chen L, Tang YW et al. Emergence of the mcr-1 colistin resistance gene in carbapenem-resistant Enterobacteriaceae. Lancet Infect Dis 2016; 16: 287-8
10. Mediavilla JR, Patrawalla A, Chen L et al. Colistin-and carbapenemresistant Escherichia coli harboringmcr-1 and blaNDM-5, causing a complicated urinary tract infection in a patient from the United States. mBio 2016; 7: e01191-16
11. vanBelkumA, Halimi D, BonettiEJ et al. Meropenem/colistin synergy testing for multidrug-resistant Acinetobacter baumannii strains by a twodimensional gradient technique applicable in routine microbiology. JAntimicrobChemother 2015; 70: 167-72
12. FanB, Guan J, WangX et al. Activity of colistin in combinationwithmeropenem, tigecycline, fosfomycin, fusidic acid, rifampin or sulbactam against extensively drug-resistant Acinetobacter baumannii in a murine thighinfectionmodel. PLoS One 2016; 11: e0157757
13. Ribera A, Benavent E, Lora-Tamayo J et al. Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapywith colistin plus b-lactams. J Antimicrob Chemother 2015; 70: 3357-65
14. Ewers C, Bethe A, Stamm I et al. CTX-M-15-D-ST648 Escherichia coli from companion animals and horses: another pandemic clone combiningmultiresistance and extraintestinal virulence? J Antimicrob Chemother 2014; 69: 1224-30
15. Hornsey M, Phee L, WarehamDW. A novel variant, NDM-5, of the New Delhi metallo-b-lactamase in amultidrug-resistant Escherichia coli ST648 isolate recovered from a patient in the United Kingdom. Antimicrob Agents Chemother 2011; 55: 5952-4
16. Sun J, Yang RS, Zhang Q et al. Co-transfer of blaNDM-5 and mcr-1 by an IncX3-X4 hybrid plasmid in Escherichia coli. NatMicrobiol 2016; 1: 16176
17. Wiegand I, Hilpert K, Hancock RE. Agar and broth dilutionmethods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 2008; 3: 163-75
18. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fifth Informational Supplement M100-S25. CLSI, Wayne, PA, USA, 2015
19. Tsuji BT, von EiffC, Kelchlin PA et al. Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the smallcolony-variant phenotype. Antimicrob Agents Chemother 2008; 52: 1533-7
20. Dudhani RV, Turnidge JD, Coulthard K et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010; 54: 1117-24
21. Ma Z, Wang J, Gerber JP et al. Determination of colistin in human plasma, urine and other biological samples using LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 862: 205-12
22. KimHJ, Seo KA, KimHMet al. Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatographyelectrospray ionization-tandem mass spectrometry. J Pharm Biomed Anal 2015; 102: 9-16
23. Cheah SE, Wang J, Nguyen VT et al. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother 2015; 70: 3291-7
24. Wang Q, Zhang Y, Yao X et al. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. Eur J Clin Microbiol Infect Dis 2016; 35: 1679-89
25. Ni W, Shao X, Di X et al. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents 2015; 45: 8-18
26. Cortes P, Blanc V, Mora A et al. Isolation and characterization of potentially pathogenic antimicrobial-resistant Escherichia coli strains from chicken and pig farms in Spain. Appl EnvironMicrobiol 2010; 76: 2799-805
27. Sherchan JB, Hayakawa K, Miyoshi-Akiyama T et al. Clinical epidemiology and molecular analysis of extended-spectrum-b-lactamase-producing Escherichia coli in Nepal: characteristics of sequence types 131 and 648. Antimicrob Agents Chemother 2015; 59: 3424-32
28. Mizuno Y, Yamaguchi T, Matsumoto T. A first case of New Delhi metallob-lactamase-7 in an Escherichia coli ST648 isolate in Japan. J Infect Chemother 2014; 20: 814-6
29. Ewers C, Bethe A, Semmler T et al. Extended-spectrum b-lactamase-producing and AmpC-producing Escherichia coli from livestock and companion animals, and their putative impact on public health: a global perspective. Clin Microbiol Infect 2012; 18: 646-55
30. Tascini C, Ferranti S, Messina F et al. In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against amultiresistant Pseudomonas aeruginosa isolate. Clin Microbiol Infect 2000; 6: 690-1
31. Bozkurt-Guzel C, Gerceker AA. In vitro pharmacodynamic properties of colistin methanesulfonate and amikacin against Pseudomonas aeruginosa. Indian JMed Microbiol 2012; 30: 34-8
32. Bozkurt-Guzel C, Gerceker AA. Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. JAntibiot 2012; 65: 83-6
33. Fulnecky EJ, Wright D, Scheld WM et al. Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. J Infect 2005; 51: e249-51
34. Tascini C, Tagliaferri E, Giani T et al. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2013; 57: 3990-3
35. Rodriguez-Avial I, Pena I, Picazo JJ et al. In vitro activity of the nextgeneration aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemaseproducing Enterobacteriaceae strains. Int J Antimicrob Agents 2015; 46: 616-21
36. Dubrovskaya Y, Prasad N, Lee Y et al. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother 2015; 70: 1903-7
37. Taccone FS, de Backer D, Laterre PF et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2011; 37: 531-5
38. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94
39. Tran TB, Velkov T, Nation RL et al. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents 2016; 48: 592-7